 MINNEAPOLIS, June 04, 2021 GLOBE NEWSWIRE -- Panbela Therapeutics, Inc. Nasdaq: PBLA, a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced the presentation of interim clinical data from its Phase 1b combination therapy study of SBP-101, a proprietary polyamine analogue, with gemcitabine and nab-paclitaxel GA in patients with metastatic Pancreatic Ductal Adenocarcinoma PDA, at the American Society of Clinical Oncology ASCO Annual Meeting taking place June 4-8, 2021. 